Literature DB >> 15827960

Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway.

Andrea Augello1, Roberta Tasso, Simone Maria Negrini, Andrea Amateis, Francesco Indiveri, Ranieri Cancedda, Giuseppina Pennesi.   

Abstract

Bone marrow mesenchymal progenitor cells (BMSC) are used for regenerating tissues of mesodermal origin, as well as tissues of different embryological derivation. Experimental evidence shows that BMSC are able to suppress the activation of the immune response by mechanisms that are still not completely understood. Thus far, in vitro studies carried using human or mouse cells indicate that autologous or allogeneic BMSC strongly suppress proliferation of T lymphocytes, triggered by cellular stimuli, nonspecific mitogenic stimuli, or antigenic peptides. Using cell proliferation and blocking assays, we demonstrated that BMSC inhibited the activation of murine splenocytes, T, and B lymphocytes. Direct contact of BMSC and target cells in a cognate fashion determined the inhibition of cell proliferation via engagement of the inhibitory molecule programmed death 1 (PD-1) to its ligands PD-L1 and PD-L2, leading the target cells to modulate the expression of different cytokine receptors and transduction molecules for cytokine signaling. Soluble factors present on supernatants of BMSC cultures were effective in suppressing proliferation of B cells to a mitogenic stimulus. Taken together, these results highlight the complexity of the role of BMSC in regulating the immune response, asserting the possibility of their therapeutic application in transplantation and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827960     DOI: 10.1002/eji.200425405

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  212 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

3.  Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.

Authors:  M J Crop; C C Baan; S S Korevaar; J N M Ijzermans; M Pescatori; A P Stubbs; W F J van Ijcken; M H Dahlke; E Eggenhofer; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 4.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

Review 5.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 6.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

7.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

8.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

9.  Use of immune modulation by human adipose-derived mesenchymal stem cells to treat experimental arthritis in mice.

Authors:  Li Zhang; Xiao-Yan Wang; Peng-Jun Zhou; Zhe He; Hai-Zhao Yan; Dan-Dan Xu; Ying Wang; Wu-Yu Fu; Bi-Bo Ruan; Sheng Wang; Hai-Xuan Chen; Qiu-Ying Liu; Yu-Xia Zhang; Zhong Liu; Yi-Fei Wang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

10.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.